Molecules of neurohypophyseal hormones have heen shown to be very flexible in solution. A conformation of oxytocin, necessary for the interaction with the uterotonic receptor, was suggested on the basis of extensive physico-chemical studies.
determination of solution conformation which might be (in the case of potent agonists or inhibitors) more similar to that which is present during interaction with the receptor. In the most favourable case, selectively acting analogs might be obtained and conformational and structural features which are important for binding and transduction can be more precisely determined. Additionally, increased enzymatic stability may be expected.
Three analogues containing Tic were synthesized. In the first one, L-Tic replaced tyrosine in position 2 ([Tic 2 , Lys'JVP (I)), and in the second one, phenylalanine in position 3 ([Tic', Lys'JVP (II)). The third analogue is the octapeptide which was isolated as a side product in an unsuccessful synthesis of an analogue containing two residues of t-Tic (des-Tyr 2-[Tic', Lys'JVP(III)).
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Syntheses of all three analogues were performed by solid phase technique on a benzhydrylamine resin. For a-amino group protection we have used the tert.butyloxycarbonyl (Boc) group. For side chain protection we have used: 2-bromobenzyloxycarbonyl (Lys), benzyl (Tyr), 4-methylbenzyl (Cys). Protected amino acids were coupled by N,N'-dicyclohexylcarbodiimide (DCC) and Nshydroxybcnzotriazclc (HOBt) in dimethylformarnide. In the case of t-Tic coupling we expected problems due to the sterically hindered secondary amino group. Condensation of the protected Tic with the free amino group proceeded smoothly, but problems arose in the subsequent coupling steps. Removal of Bee-protection required repeated exposure to trifluoroacetic acid or the use of a higher concentration of this acid. Since the secondary amino group of Tic does not give a positive ninhydrin test, we employed the 'chloranil test". We also tested the possibility of determining the free secondary amino group by its acylation using a large excess of an amino acid not contained in the sequence of vasopressin and, simultaneously, with a high probability of easy coupling. We used alanine and the remaining free secondary amino group was determined by amino acid analysis. Acylation of the Tic amino group proceeded extremely slowly, and complete coupling was achieved only after an addition of dimethylarninopyridine. We have not succeeded in acylation of Tic by a second Tic residue, and the attempt to synthesize [Tic 2 , Tic'JVP led only to the isolation of the analogue III as the main product.
Side chain protecting groups were cleaved simultaneously with the cleavage of the peptide from the resin by liquid hydrogen fluoride. Sulfhydryl groups oxidation was performed with potassium ferricyanide and the analogues were purified by HPLC and gel filtration. The large decrease in potency of compounds I and II is most probably due to the conformational changes of the molecule which are related to the conformational constraints imposed by a Tic residue in position 2 and/or 3 of vasopressin. Prochazka, Ancans, Slanincva, Machova, Barth, Lebl:
formance liquid chromatography (HPLC) was carried out on an SP~8700 instrument equipped with an SP-8400 detector and SP-4100 integrator (all from Spectra Physics, Santa Clara, U.S.A.). Preparative liquid chromatography was carried out on a Modulprep preparative liquid chromatograph (Jobin Yvon, Longjumeau Cedex, France). As the final purification step, Biegel P-2 column chromatography in 1M acetic acid was employed (I X 100 em). Chelaton III was added to the sample in order to remove the residues of heavy metals, if present. Before use, all amino--acid derivatives were subjected to ninhydrin tests.
Solid-phase peptide synthesis:
A cycle for incorporation each amino acid residue into the growing peptide chain consisted of the iollowing: 1) washing with dlchloromethane (3 X 20 rnl, I min/wash); 2) cleaving the Boc group by adding 20 ml of 45% trifluoracetic acid in dichloromethane containing 5% anisole, one treatment for 5 min, the second one for 30 min; 3) washing with dichloromethane (3 X 20 ml, I min/wash); 4) washing with isopropanol (3 X 20 ml, I min/wash); 5) washing with dichloromethane (3 X 20 ml, 1 min/wash); 6) neutralizing by addition 5% diisopropylethylamine in dlchloromethane (2 X 20 ml, 2 min/wash); 7) washing with dichloromethane (4 X 20 mI, I min/wash); 8) washing with dimethylformamide (3 X 20 mI, 1 min/wash); 9) addition of the Bee-protected amino acid derivative in 20 mI of dimethylformamide followed by HOBt, followed by DCCI and stirring for O'5-16 h; 10) washing with dimethylformamide (3 X 20 mI, 1 min/wash); 11) washing with dichloromethane (3 X 20 ml, 1 minI /wash). Between steps 9 and 10, several milligrams of the resin were removed and used for ninhydrin tesr'' to determine the progress of the coupling. In the case of the coupling onto the imino group of proline or Tic the chloranil rest" was used.
Ntl._Tert .butyloxycarbonylglycyl-resin
Benzhydrylamine resin (VCB, 0'6 mmol/g, 2·5 g) was suspended in dichloromethane, washed with dimethylformamide and coupled with 3 molar excess of Ns-tert.butyloxycarbonylglycine, Nehydroxybenzotriazole and dicyclohexylcarbcdiirnide in dimethylformamide. Coupling was interrupted after 2 h, the resin was washed consequently with dimethylformamidc (3 X 30 rnl) and dichloromethane (3 X 30 ml) and the substitution of 0'56 mmoljg was determined by quantitative amino acid analysis. Free amino groups were acetylatcd with a mixture of 5 ml acetanhydride and 2 mI triethylamine in 50 ml dichloromethane for 3 h.
Hexapeptide-resin (Peptide-resin A)
The synthesis was performed according to the general scheme given above. Boc-amino acids were coupled to the resin by the DCCr/HOBt procedure. All reagents were used in 3 molar excess and the coupling was monitored by ninhydrin or ehloranil test. protected derivatives were used in the following order: Boc-Lys(2-Br~Z)-OH (ref,9), Boc-Pro-Ohl, Boc-Cysfsl-Me-Bzlj-Ol-i (ref,lO) Boc-Asn-Ol-l and Boc-Gln-Ol-i. Finally, the Bee-group was cleaved from the hexapeptide-resin, the resin was washed and dried.
[2-(1,2,3,4-Tetrahydroisoquinolinc-3-carboxylic acid), a-lysine[vasopressin (I) Peptide-resin A (1'3 g, 0'5 mmol) was acylated according to the general scheme with Boc-Phe-Of-l, Boc-Tic-Ol-l (ref.
l l ) and Bcc-Cysfq-Me-Bzlj-Ol-l (ref.!O). The deprotection of Boo-octapeptideresin was achieved by the treatment with 45% TFA and 1O~~anisole in dichloromcthane (5 min and 1 h), followed by 60 min treatment in 95% TFA with 5~~of anisole. Deprotection was checked by acetylation'P and chloranil test", Condensation of the cysteine derivative was performed for 3 h and after this period it was repeated with the addition of dimethylaminoCollect. Czech. Chern. Cornrnun. (Vol. 55) (1990) pyridine. Finally, the Bee-group was cleaved from the nonapeptide-resin, the resin was washed and dried (1-35 g), and treated with liquid hydrogen fluoride (IO ml, 60 min, O°C) in the presence of thioanisole (l ml). The unprotected nonapeptide, together with the resin, was triturated with ethyl acetate after evaporation of the hydrogen fluoride, filtered off, washed with ethyl acetate and the free peptide was extracted successively by acetic acid, 50% acetic acid, water and Iyophilized. The lyophilizate (0'48 g) was dissolved in water (500 ml) and the pH of the solution was adjusted with O'IM-NaOH to 7'0. Potassium ferricyanide (I 80 mg in 60 ml of water) was added to this solution in a period of 10 min. During the oxidation (20 min), pH was maintained at 7'0 by addition ofO'IM~NaOHand after oxidation adjusted with acetic acid to 4'5. The solution was put onto a column of Amberlite CO-SOl, the column was washed with 0'25% acetic acid and the product eluted with 50% acetic acid. After freeze-drying, the product (370 mg} was purified by HPLC (Separon SIX C-18, 7 urn, 25 X 0'8 ern). Elution with methanol-0'05% trlfluoroacetic acid mixture (3: 7) and lyophilization of the corresponding fractions afforded 105 mg (15%, based on the glycine-resin) of the product, pure according to HPLC (k' 3'96; methanol-0'05% trifluoroacetic acid 4: 6). Gel filtration of a part (50 mg) of this product on Biegel P2 column (I X 100 ern) in 1M acetic acid afforded two peaks of the same amino acid composition. The first, probably the dimer, was eluted at 72 ml (5 mg), the second at 76 ml 
Heptapeptide-resin (Peptide-resin B)
Peptide-resin A (2'6 g, 1'0 mmol) was coupled with Boc-Tic-Obl (reC lt ) (2'5 h). The dcprotecuon of Boc-heptapeptide-resin was performed by the treatment with 45% TFA and 10% anisole in dichloromethane (5, 30 and 60 min). Deprotection was checked by acetylation test 12 and chloranil test 4.A small sample of the resin was quantitatively acylated by Boc-Ala-Ol-l and tested by amino acid analysis. Only 75% incorporation oralanine was found and therefore deprotection was continued for another 90 min in 95% TFA with 5% of anisole. Yield: 3'0 g.
[3~( 1,2,3,4~Tetruhydroisoquinoline-3-carboxylic acid), Belysiuejvasopresein (Il) Peptide-resin B (1'5 g, 0'5 mmol) was coupled ao ording to the general scheme with Boc-Tyr--OH, and Boc-Cysf-l-Me-Bzlj-Of-l (ref. I O). Condensation of tyrosine derivative was performed for 4 h and after this period it was repeated with the addition of dimethylaminopyridine. Finally the Boo-group was cleaved from the nonapeptide-resin, the resin was washed and dried (I'50 g) and was treated with liquid hydrogen fluoride (to mI, 60 min, DOC) in the presence of thioanisolc (I ml). Oxidation of the unprotected nonapeptide was performed analogously to the above described procedure. The product after desalting 070 mg) was purified by I-IPLC (Separon SI-C-18, 10 urn, 35 X 2 em). Elution with a mett.anol-0·05% trifluoroacetic acid mixture (step Des-2~tyrosine-[3-( I,2,3,4-tetrahydroisoq uinoline-3-ca rb oxylie aei d),
8-1ysine}vasopressin (III)
Analogue III was isolated as the main product from the mixture resulting from the attempt to synthesize [2,3-(1,2,3,4-tetrahyctroisoquinoIine-3-carboxylic acid), Svlysinejvasopressin. The synthesis performed as described above afforded after freeze-drying 350 mg of crude peptide. One part (150 rng) was purified by HPLC (Separon SIX C-18, 7 Pharmacological Methods AU pharmacological tests were performed using wtsrar rats weighing 200-300 g. The uterotonic potency in vitro was evaluated using the Holton procedure 1 3,14 in Munsick 14 solution, and in vivo, according to reL I S . The galactogogic potency in vivo was established according to refs l 6 • 1 7 . Pressor activity was tested on pithed rat preparation according to refs 1 8 • 19 • The activity on unanacsthetized rat was evaluated by modified Burn's method 20 . 21 . Male rats (160 to 200 g) after overnight fasting with free access to water were applied the water load (4 mi/IOO g) per os and at the same time, s.c. injection of the tested compound or standard preparation was administered. Urine was collected for 5 h and its volume was read every 15 min. The time in minutes (T I / 2 ) in which one, half of the water load was excreted was taken as a measure for the delay of water diuresis. LVP was used as the standard at dose 1'0 mU/IOO g in 0'2 ml. Analogues I and II were applied at doses from ZOO to 18 000 ng/lOO g, analogue III at doses up to 10 000 ng/100 g. Control rats were injected with physiological solution.
